# Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis

> **NCT00116454** · PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 73 (actual)

## Conditions studied

- Carcinoma, Hepatocellular
- Hepatitis, Viral, Human

## Interventions

- **DRUG:** 131 I-lipiodol

## Key facts

- **NCT ID:** NCT00116454
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116454, "Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00116454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*